BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 17032555)

  • 1. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG
    Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumors: current management.
    Pisters PW; Patel SR
    J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
    Nilsson B; Nilsson O; Ahlman H
    Expert Opin Investig Drugs; 2009 Apr; 18(4):457-68. PubMed ID: 19335275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
    Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to imatinib- and sunitinib-resistant GIST.
    Reichardt P
    Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
    Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G
    J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of gastrointestinal stromal tumors--a comprehensive review.
    Lai EC; Lau SH; Lau WY
    Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 19. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
    Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
    World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.